Formulation Development
Passage Bio Closes $110-Million Series B Financing
Passage Bio recently announced the closing of a $110-million Series B financing. The financing round was led by Access Biotechnology with participation from existing investors,…
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs Into Clinical Trials
This financing is intended to support two clinical trial programs of NKX101, Nkarta’s allogenic NK cell therapy targeting NKG2D, in patients with either…..
Foamix Announces New US Patent That Expires in 2037
Foamix Pharmaceuticals Ltd. recently announced the US Patent and Trademark Office has issued US Patent No. 10,398,641 covering a method of treating…….
Kintai Therapeutics Announces Collaborations With Leading Academic Centers
Kintai Therapeutics recently announced it has established new collaborations with leading academic institutions to identify novel molecules that play a fundamental role in microbe to…
PCI Strengthens Position in Europe With Investment in Ireland
PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has solidified its leadership position in the EU with strategic investment to deepen its presence…
Adaptimmune & Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products
Adaptimmune Therapeutics plc and Noile-Immune Biotech, Inc. recently announced they will co-develop next-generation SPEAR T-cell products, incorporating Noile-Immune’s PRIME (proliferation inducing and migration enhancing) technology,…
Hovione Signs Collaboration Agreement With Kiel University on High-Dose Dry Powder Inhalation Delivery
Hovione Technology recently announced it has entered into a collaboration agreement with Kiel University, Institute of Pharmacy in Germany, a reference research institution on inhaled drug delivery.
BIOLOGICS DELIVERY - Enabling Biologic Drug Delivery of Volumes Beyond 1 mL
Megan Lan, MBA, MA, and Patrick Le Gal say delivery system manufacturers need to use methodologies and tools to manage conflicting requirements and to offer delivery solutions that balance performance, robustness, and usability while delivering higher volume or viscosity biologics.
INTRATUMORAL DELIVERY - Arming the Immune System; Turning Cold Tumors Hot
Daniel J. O’Connor believes a trigger mechanism that can turn cold tumors hot can help researchers set their focus on delivering potentially life-saving drugs directly to core of a cancerous tumor.
ON-TARGET DELIVERY - Lipid-Based System Introduces a Novel Approach for an HIV Vaccination
Fabrice Navarro, PhD, summarizes recent disappointing clinical trial results for HIV vaccines and reports on CEA-Leti’s new approach based on engineered lipid nanoparticles that deliver p24 (a viral protein that optimizes the CpG adjuvant’s effect) with pinpoint accuracy.
Ajinomoto Bio-Pharma Services Acquires Remaining Interest in Granules OmniChem Joint Venture in India
Ajinomoto Bio-Pharma Services recently announced its intention to purchase the remaining 50% ownership interest in its Visakhapatnam, India, joint venture, Granules OmniChem Private Limited (GOC) from its….
THERANOSTICS - The Outlook for the Theranostic Radionuclide Approach to Neuroendocrine Tumors & Other Cancers
Eric P. Krenning, MD, PhD, and Rachel Levine provide a review of the evolution and development of theranostics, in general, citing the theranostic radionuclide approach to the management of neuroendocrine tumors to highlight this evolving modality.
EXECUTIVE INTERVIEW - Eloxx Pharmaceuticals: Developing Rare Disease Drugs for Nonsense Mutations
Bob Ward, Chairman and CEO at Eloxx Pharmaceuticals, discusses nonsense mutations and how his company’s goal is to bring safe and effective therapies to children and adults suffering from genetic diseases as quickly as possible.
Ivy Brain Tumor Center & Salarius Pharmaceuticals Launch Collaborative Partnership
The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. recently announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat,…
Aptinyx Presents Data Demonstrating Positive Activity on Cognitive Performance & Biomarkers in a Preclinical Model
Aptinyx Inc. recently announced the presentation of preclinical data on its novel NMDA receptor modulator, NYX-458. The product candidate demonstrated positive recovery of performance on…
Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial
Landos Biopharma, Inc. recently announced dosing of the first patient in a Phase 2 study evaluating the safety and efficacy of BT-11 in patients with…
MyoKardia Begins Dosing in Phase 1 Clinical Study
MyoKardia, Inc. recently announced it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for…
